Please select the option that best describes you:

Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?  

Efficacy and cardiovascular safety appear similar per the PATCH trial updated at ESMO 2024. How would you counsel patients who decline LHRH agonists?



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more